A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) NaΓ―ve Women (ARIA)
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- Drug: Dolutegravir/abacavir/lamivudine FDCDrug: AtazanavirDrug: RitonavirDrug: Tenofovir/emtricitabine FDC
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 499
- Registration Number
- NCT01910402
- Locations
- π¬π§
GSK Investigational Site, Tooting, London, United Kingdom
An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- HIV-associated Lipodystrophy Syndrome
- Interventions
- Drug: GSK1265744B (sodium salt) containing 14C-GSK1265744BDrug: 150 mg GSK1265744BDrug: Placebo
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 16
- Registration Number
- NCT01848340
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
Phase 2
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- Drug: AtazanavirDrug: BMS-955176Drug: Placebo matching with BMS-955176Drug: TenofovirDrug: RitonavirDrug: Emtricitabine
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 107
- Registration Number
- NCT01803074
- Locations
- π©πͺ
GSK Investigational Site, Berlin, Germany
An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
- Conditions
- Infection, Human Immunodeficiency Virus
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT01776996
- Locations
- π¨π
GSK Investigational Site, Zuerich, Switzerland
A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 24
- Registration Number
- NCT01762995
A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Phase 1
Completed
- Conditions
- Infections, Human Immunodeficiency Virus and Herpesviridae
- Interventions
- Drug: GSK1265744 injectable suspensionOther: Placebo to match injectable suspension
- First Posted Date
- 2012-12-25
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 72
- Registration Number
- NCT01756131
A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: GSK1265744 30 mg oralDrug: Midazolam 3 mg oral + GSK1265744 30mg oralDrug: GSK1265744 400 mg (200 nm)Drug: GSK1265744 400 mg (1 micro m)Drug: GSK1265744 400 mg (5 micro m)
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 43
- Registration Number
- NCT01754116
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Relative Bioavailability Study of GSK1265744 Formulations
Phase 1
Completed
- Conditions
- Infections, Human Immunodeficiency Virus and Hepatitis
- Interventions
- Drug: GSK1265744 Na Salt TabletsDrug: GSK1265744 Free Acid Nanomilled CapsulesDrug: GSK1265744 Free Acid Micronized Capsules
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 18
- Registration Number
- NCT01648257
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Phase 2
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- Drug: Efavirenz 600 mgDrug: GSK1265744 10 mgDrug: GSK1265744 30 mgDrug: GSK1265744 60 mgDrug: Rilpivirine 25 mgDrug: PlaceboDrug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 244
- Registration Number
- NCT01641809
- Locations
- π¨π¦
GSK Investigational Site, Montreal, Quebec, Canada
Evaluation of the Bioequivalence of a Combined Formulated Tablet
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 66
- Registration Number
- NCT01622790
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Β© Copyright 2025. All Rights Reserved by MedPath